


Pilaralisib

Cat. No.:	HY-16526		
CAS No.:	934526-89-3		
Molecular Formula:	C ₂₅ H ₂₅ ClN ₆ O ₄ S		
Molecular Weight:	541.02		
Target:	PI3K		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (184.84 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.8484 mL	9.2418 mL	18.4836 mL
	5 mM	0.3697 mL	1.8484 mL	3.6967 mL
	10 mM	0.1848 mL	0.9242 mL	1.8484 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (4.62 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (4.62 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC₅₀s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.

IC₅₀ & Target

IC ₅₀ & Target	PI3Kγ	PI3Kδ	PI3Kα	PI3Kβ
	23 nM (IC ₅₀)	36 nM (IC ₅₀)	39 nM (IC ₅₀)	383 nM (IC ₅₀)
	Vps34 6974 nM (IC ₅₀)	DNA-PK 4750 nM (IC ₅₀)		

In Vitro	<p>Pilaralisib (XL147) displays potent inhibitory activity against Class I PI3K isoforms p110α, p110δ, and p110γ, with IC₅₀s of 39, 36, and 23 nM, respectively. Pilaralisib (XL147) is less potent against the remaining Class I isoform, p110β, with an IC₅₀ value of 383 nM. The IC₅₀ value for inhibition of PI3Kα by Pilaralisib (XL147) is determined at various concentrations of ATP, revealing XL147 to be an ATP-competitive inhibitor with an equilibrium inhibition constant (K_i) value of 42 nM. Pilaralisib (XL147) has relatively weak inhibitory activity toward the class III PI3K vacuolar sorting protein 34 (VPS34; IC₅₀ value of ~7.0 M) and the PI3K-related DNA-dependent protein kinase (DNA-PK; IC₅₀ value of 4.75 μM). In an mTOR kinase immunoprecipitation assay using cell lysates, Pilaralisib (XL147) does not inhibit mTOR activity toward the physiologic substrate protein eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1; IC₅₀>15 μM). Consistent with its inhibitory activity against purified PI3K proteins, Pilaralisib (XL147) inhibits EGF-induced PIP₃ production in PC-3 and MCF7 cells in serum-free medium with IC₅₀s of 220 and 347 nM, respectively. The ability of Pilaralisib (XL147) to inhibit phosphorylation of key signaling proteins downstream of PI3K is examined by assessing its effects on EGF-stimulated phosphorylation of AKT and on nonstimulated phosphorylation of S6 in PC-3 cells in serum-free media by cell-based ELISA. Pilaralisib (XL147) inhibits these activities with IC₅₀s of 477 and 776 nM, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>The ability of Pilaralisib (XL147) to inhibit this endogenous phosphorylation of AKT, p70S6K, and S6 is examined following a single oral dose of 10, 30, 100, or 300 mg/kg. The tumors are harvested 4, 24, or 48 hours postdose and homogenized in lysis buffer. Tumor lysates from each animal (n=4) are then pooled for each group and analyzed for levels of total and phosphorylated AKT, p70S6K, and S6 by Western immunoblotting. Administration of Pilaralisib (XL147) causes a dose-dependent decrease in phosphorylation of AKT, p70S6K, and S6 in the tumors, reaching a maximum of 81% inhibition of AKT phosphorylation at 300 mg/kg at 4 hours. The dose-response relationships derived from the 4-hour time point predict 50% inhibition of AKT, p70S6K, and S6 phosphorylation at doses of approximately 100 mg/kg (pAKT^{T308}), 54 mg/kg (pAKT^{S473}), 71 mg/kg (p-p70S6K), and 103 mg/kg (pS6). The inhibition of AKT, p70S6K, and S6 phosphorylation in MCF7 tumors following a 100 mg/kg dose of Pilaralisib (XL147) is maximal at 4 hours, reaching 55% to 75%; however, the level of inhibition decreased to 8% to 45% by 24 hours, and only minimal or no inhibition was evident by 48 hours. Following a 300 mg/kg dose of Pilaralisib (XL147), inhibition is also maximal at 4 hours (65%-81%). However, in contrast with the 100 mg/kg dose, inhibition at 24 hours (51%-78%) is almost comparable with that seen at 4 hours, and partial inhibition (25%-51%) persisted through 48 hours^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

PROTOCOL

Cell Assay ^[1]	<p>MCF7 human mammary carcinoma cells and PC-3 human prostate adenocarcinoma cells are maintained in culture conditions at 37°C under 5% CO₂. For PI3K pathway status assessment following EGF treatment, the culture medium is replaced with test compounds dissolved in serum-free DMEM containing 0.3% DMSO. After incubation for 3 hours, cells are stimulated with 100 ng/mL of EGF for 10 minutes and Western immunoblot analysis of cell lysates is performed. Assessment of mTOR pathway status in Ramos cells is performed. Cellular proliferation is assessed using the Cell Proliferation ELISA, bromodeoxyuridine (BrdUrd) chemiluminescence kit. Cytotoxicity, apoptosis (caspases-3/7), anchorage-independent growth, and PC-3 cell migration assays are performed. Hepatocyte growth factor (HGF)-induced chemotaxis is assessed. The endothelial cell tube formation assay is performed, with minor modifications. Total tube length is quantified with Image Pro Plus software^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
Animal Administration ^[1]	<p>Mice^[1]</p> <p>Female athymic nude mice and male nude mice are used. Tumor cells are cultured and established as xenografts in mice, and body and tumor weights assessed. Statistical significance is determined using the two-tailed Student t test (significance defined as P<0.05). Pilaralisib (XL147) is formulated in sterile water/10 mmol/L HCl or water and administered at the indicated doses and regimens by oral gavage at a dose volume of 10 mL/kg.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Cell Syst. 2020 Jan 22;10(1):66-81.e11.
- Methods Mol Biol. 2018;1711:351-398.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Foster P, et al. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models. Mol Cancer Ther. 2015 Apr;14(4):931-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA